BRIEF published on 10/23/2024 at 11:33, 29 days 1 hour ago The Capital Group crosses the threshold in ESSILORLUXOTTICA Voting Rights Acquisition Of Shares Threshold Crossing EssilorLuxottica The Capital Group
BRIEF published on 10/02/2024 at 07:05, 1 month 19 days ago EssilorLuxottica completes acquisition of majority stake in Heidelberg Acquisition Medical Technologies Ophthalmology Heidelberg EssilorLuxottica
BRIEF published on 10/02/2024 at 07:05, 1 month 19 days ago EssilorLuxottica Completes Acquisition of Supreme® from VF Corporation Acquisition EssilorLuxottica Optical Industry Supreme® VF Corporation
BRIEF published on 09/17/2024 at 18:50, 2 months 3 days ago EssilorLuxottica unveils its future headquarters in Paris Innovation Sustainability Paris EssilorLuxottica Head Office
PRESS RELEASE published on 09/17/2024 at 18:45, 2 months 3 days ago EssilorLuxottica unveils plans for its new corporate headquarters in Paris EssilorLuxottica announces plans for new global headquarters in Paris at Place Valhubert, Paris 13e, embracing innovation, sustainability, and employee well-being Innovation Sustainability Paris EssilorLuxottica Global Headquarters
BRIEF published on 09/17/2024 at 07:39, 2 months 4 days ago EssilorLuxottica and Meta Extend Partnership to Shape Future of Smart Eyewear EssilorLuxottica Smart Eyewear Wearables Meta Platforms Ray-Ban
PRESS RELEASE published on 09/17/2024 at 07:34, 2 months 4 days ago EssilorLuxottica and Meta Announce Long Term Partnership, Shaping the Future of the Smart Eyewear Category EssilorLuxottica and Meta extend partnership to develop multi-generational smart eyewear products, revolutionizing wearables. Ray-Ban Meta glasses redefine connected living Partnership Meta EssilorLuxottica Smart Eyewear Ray-Ban Meta Glasses
BRIEF published on 08/29/2024 at 19:51, 2 months 22 days ago EssilorLuxottica: Successful Euro 2 Billion Bond Issuance at 2.99% Euronext Paris Institutional Investors Bond Issuance EssilorLuxottica Euro 2 Billion
PRESS RELEASE published on 08/29/2024 at 19:46, 2 months 22 days ago EssilorLuxottica: successful Euro 2 billion bond issuance at 2.99% EssilorLuxottica successfully issues Euro 2 billion bonds at 2.99%, attracting quality institutional investors. Proceeds for general corporate purposes Institutional Investors Financial Market Corporate Purposes EssilorLuxottica Euro 2 Billion Bonds
BRIEF published on 07/26/2024 at 18:35, 3 months 25 days ago EssilorLuxottica: Publication of the 2024 Interim Financial Report Financial Statements 2024 Interim Report Board Approval EssilorLuxottica
Published on 11/21/2024 at 13:00, 29 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 29 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 29 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 29 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 29 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 54 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 14 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 31 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 9 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 44 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 44 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
